Cytalux
Phase 3Small molecule
Cytalux is one of 28 small molecule programs targeting Gastrointestinal Cancer. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Intraoperative
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
IC-Green
PProvepharm SAS
Approved
Ketalar
AAultman Health Foundation
Approved
Anerem
AAcacia Pharma Ltd
Approved
Reglan
IIstituto Clinico Humanitas
Approved
Ciprofol
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Marcaine
IInnocoll
Phase 2
MS Contin
HHikma Pharmaceuticals LLC
Phase 2
Vancocin
HHikma Pharmaceuticals LLC
Phase 2
Cytalux
OOn Target Laboratories, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometrial Cancer1 trial
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Recruiting·—·Phase 1·NCT07278986·10 enrolled
Intraoperative1 trial
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Recruiting·—·Phase 1·NCT06235125·10 enrolled
Gastrointestinal Cancer1 trial
Lung1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cytalux. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOn Target Laboratories, LLC